Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
This is where intranasal delivery stands out
But reassuring is not the same as proven safe
Community protocols typically run 8 weeks on, 8 weeks off, generally for cost and IGF-1 normalization
Both peptides may be used under medical supervision when prescribed and monitored appropriately
US$ 27.70
US$ 23.84
US$ 24.96
US$ 24.97
US$ 25.58
